Journal article · 2021 · Open access

Alzheimer's disease drug development pipeline: 2021

Jeffrey L. Cummings, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Kazem Taghva

Alzheimer s & Dementia Translational Research & Clinical Interventions, 7(1), e12179 · Published 1 January 2021 · DOI 10.1002/trc2.12179

Free PDFView at the publisherCite this paper

In brief

“Alzheimer's disease drug development pipeline: 2021” is a 2021 journal article by Jeffrey L. Cummings and 4 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 589 citations as of 15 November 2026, which puts it in the top 5% of works published in 2021 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Citations
589
Most cited in
2022 (162)
Field-weighted impact
37.07
References
38
Authors
5

Abstract

INTRODUCTION: The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD. METHODS: We interrogated ClinicalTrials.gov, the federal registry of clinical trials to identify drugs in trials. RESULTS: There are 126 agents in 152 trials assessing new therapies for AD: 28 treatments in Phase 3 trials, 74 in Phase 2, and 24 in Phase 1. The majority of drugs in trials (82.5%) target the underlying biology of AD with the intent of disease modification; 10.3% are putative cognitive enhancing agents; and 7.1% are drugs being developed to reduce neuropsychiatric symptoms. DISCUSSION: This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of AD.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cummings, J. L., Lee, G., Zhong, K., Cacho, J. R. F., & Taghva, K. (2021). Alzheimer's disease drug development pipeline: 2021. Alzheimer s & Dementia Translational Research & Clinical Interventions, 7(1), e12179. https://doi.org/10.1002/trc2.12179

MLA 9

Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2021.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 7, no. 1, 2021, p. e12179. https://doi.org/10.1002/trc2.12179.

Chicago

Cummings, Jeffrey L., Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, and Kazem Taghva. 2021. “Alzheimer's disease drug development pipeline: 2021.” Alzheimer s & Dementia Translational Research & Clinical Interventions 7 (1): e12179. https://doi.org/10.1002/trc2.12179.

Harvard

Cummings, J. L. et al. (2021) ‘Alzheimer's disease drug development pipeline: 2021’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 7(1), p. e12179. doi:10.1002/trc2.12179.

IEEE

J. L. Cummings, G. Lee, K. Zhong, J. R. F. Cacho, and K. Taghva, “Alzheimer's disease drug development pipeline: 2021,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 7, no. 1, p. e12179, 2021, doi: 10.1002/trc2.12179.

BibTeX

@article{cummings2021alzheimer,
  title     = {{Alzheimer's disease drug development pipeline: 2021}},
  author    = {Cummings, Jeffrey L. and Lee, Garam and Zhong, Kate and Cacho, Jorge Ramón Fonseca and Taghva, Kazem},
  journal   = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year      = {2021},
  volume    = {7},
  number    = {1},
  pages     = {e12179},
  doi       = {10.1002/trc2.12179},
  url       = {https://doi.org/10.1002/trc2.12179}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202033
20215353
2022162162
2023107107
20249090
2025112112
20266262

Its field-weighted citation impact is 37.07: it has been cited 37.07 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • drug development pipeline
  • clinical trials
  • disease-modifying therapy
  • cognitive enhancement
  • neuropsychiatric symptoms
  • drug repurposing
  • biomarkers

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Cummings, J. L., Lee, G., Zhong, K., Cacho, J. R. F., & Taghva, K. (2021). Alzheimer's disease drug development pipeline: 2021. Alzheimer s & Dementia Translational Research & Clinical Interventions, 7(1), e12179. https://doi.org/10.1002/trc2.12179

How many times has this paper been cited?

589 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Who wrote this paper?

Jeffrey L. Cummings, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Kazem Taghva.

What is the DOI of this paper?

10.1002/trc2.12179. The permanent link is https://doi.org/10.1002/trc2.12179.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.